Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CTKB vs MXCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CTKB Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–2 Matrix Metrics)

CTKB Overall Winner 6-Pillar Tally: CTKB 5 – 0 MXCT (1 Tie) Matrix Metrics: CTKB 6 – 2 MXCT

As of Nov 20, 2026, Cytek Biosciences, Inc. (CTKB) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CTKB carries a Unified Composite Score of 48.4/100 (HOLD) at $6.12 (N/M Forward P/E, -22.5% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).

  • Growth vs. Quality Trade-Off: CTKB earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. MXCT 41.7/100 SELL) and 0.71β · 67% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CTKB vs MXCT
CTKB NASDAQ Head-to-Head Winner
Cytek Biosciences, Inc. Common Stock
Laboratory Analytical Instruments
$6.12
-3.16% 1D
Market Cap $826.6M
TTM Revenue $208M
Forward P/E N/M
Beta / 30D Vol 0.71β · 67% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 44.0 Flow 60.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.6% over 20 days), RSI 57
RSI-14: 56.9 · SMA20: $5.89 · SMA50: $5.63
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25

6-Pillar Scorecard Institutional Category Breakdown (CTKB 5 – 0 MXCT)

Columns: Metric · CTKB · MXCT
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.8x 3.9x
2. Growth & Scale CTKB
Revenue Growth (YoY) +1.8% +48.7%
Earnings Growth (YoY) +73.5% +0.0%
TTM Revenue (USD) $208M $34M
Market Cap $826.6M $132.2M
3. Profitability & Quality CTKB
Gross Margin 53.4% 81.0%
Operating Margin -22.5% -85.5%
Net Profit Margin -39.1% -81.4%
Return on Equity (ROE) -23.2% -16.9%
4. Balance Sheet & Cash Flow CTKB
Cash Generation (TTM) -$14M -$24M
Cash Flow Margin -6.6% -69.2%
Net Cash / Leverage $42M Net Cash $2.2M Net Debt (0.11x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CTKB
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 0.1% (<1st %ile) N/A (N/A)
Put/Call OI Skew 0.03x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat CTKB
OpEx & R&D Intensity 75.9% of Rev ($158M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CTKB (6) vs MXCT (2)
Institutional Metric CTKB MXCT Criterion Row Edge
Market Capitalization
Scale
$826.6M $132.2M Larger Scale CTKB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+1.8% +48.7% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-22.5% -85.5% Higher Margin CTKB
Net Profit Margin
Profitability
-39.1% -81.4% Higher Margin CTKB
Return on Equity (ROE)
Capital Efficiency
-23.2% -16.9% Higher ROE MXCT
52-Week Range Position
Momentum
91% ($3–$6) 63% ($1–$2) Stronger Trend CTKB
Beta / 30D Volatility
Risk Regime
0.71β · 67% Vol 1.19β · 96% Vol Lower Realized Risk CTKB
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite CTKB
Trailing 12M Revenue (USD)
Operating Scale
$208M $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.4% 81.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.8x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$14M ($42M Net Cash) -$24M ($2.2M Net Debt (0.11x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CTKB +16.91 pp
CTKB: +12.71% · MXCT: -4.2%
3M Horizon CTKB +39.28 pp
CTKB: +37.84% · MXCT: -1.44%
6M Horizon CTKB +20.89 pp
CTKB: +52.62% · MXCT: +31.73%
1Y Horizon CTKB +35.76 pp
CTKB: +16.35% · MXCT: -19.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CTKB Revenue MXCT Revenue CTKB Op. Margin MXCT Op. Margin Margin Leader
FY2019 N/A $10M N/A -93.7% MXCT
FY2020 $90M $20M 14.7% -71.6% CTKB
FY2021 $130M $20M 7.2% -84.3% CTKB
FY2022 $160M $30M -1.1% -95.2% CTKB
FY2023 $190M $20M -14.4% -247.7% CTKB
FY2024 $200M $20M -10.2% -230.5% CTKB
FY2025 $200M $20M -20.0% -247.6% CTKB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CTKB CONSOLIDATION
16d in phase · OBV ACCUMULATION
Current IV 0.1%
IV Percentile <1st %ile
Put/Call OI Skew 0.03x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CTKB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CTKB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $826.6M market capitalization and -22.5% operating margin.
OpEx & R&D Reinvestment 75.9% of Rev ($158M)
90D Engineering Disclosures 0 Published
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CTKB vs MXCT Key Questions & Quantitative Answers

As of Nov 20, 2026, Cytek Biosciences, Inc. (CTKB) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CTKB carries a Unified Composite Score of 48.4/100 (HOLD) at $6.12 (N/M Forward P/E, -22.5% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Growth vs. Quality Trade-Off: CTKB earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. MXCT 41.7/100 SELL) and 0.71β · 67% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

CTKB leads the Growth & Scale pillar: CTKB posts +1.8% YoY revenue growth and +73.5% YoY earnings growth on $208M TTM revenue (53.4% gross margin, -22.5% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), CTKB cumulative revenue shifted +122.2% while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, CTKB deploys 75.9% of Rev ($158M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.

CTKB and MXCT trade at balanced relative valuation multiples. CTKB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.8x EV/Revenue (-6.6% FCF margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CTKB (-23.2% ROE) versus MXCT (-16.9% ROE) capital efficiency.

In options market volatility and institutional positioning, CTKB carries 0.1% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.71β · 67% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.